VRTXON

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

VardasVRTXON

ReitingasNo.3709

Rinkos kapitalizacija$0.00

Visiškai sumažinta rinkos kapitalizacija$0.00

Rinkos dalis%

Prekybos apimtis / rinkos kapitalizacija (24 val.)0.00%

Cirkuliuojantis kiekis0.35953858

Maksimali pasiūla0

Bendra pasiūla0.35953858

Cirkuliacijos norma%

Išleidimo data--

Kaina, už kurią turtas buvo išleistas pirmą kartą--

Visų laikų rekordas466.35223147502205,2026-03-26

Mažiausia kaina432.04959348516377,2026-03-27

Vieša blokų grandinėETH

ĮvadasVertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Sektorius

Socialinė žiniasklaida

• Oficiali svetainė
• Blokuoti naršyklę

etfindex:mc_etfindex_sourceAtsisakymas: cmc pateikti duomenys ir neturėtų būti laikomi investavimo patarimais.